5 documents found, page 1 of 1
New prospects for the management of cardiovascular effects of tyrosine kinase i...
Almeida, Ana G.; Almeida, António; Melo, Teresa; Guerra, Lurdes; Lopes, Luís; Ribeiro, Patrícia; Duarte, Marta; Mota, AlexandraThe use of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia has significantly altered the prognosis of this disease, enabling close to normal life expectancy. Despite their undeniable benefits, the use of TKIs is associated with an increased risk of side effects on the cardiovascular system, particularly of atherothrombotic events. It is therefore necessary to understand and preve...
Cardiotoxicity in hematological diseases : are the Tyrosine Kinase inhibitors I...
Francisco, Ana Rita G.; Alves, Daniela; David, Cláudio; Guerra, Lurdes; Pinto, Fausto J.; Almeida, Ana G.Chemotherapy-induced cardiotoxicity is a growing concern. The cardiotoxic impact of new drugs such as tyrosine kinase inhibitors is unknown, especially the ones used for chronic myeloid leukemia. We aim to evaluate nilotinib- and imatinib-induced cardiotoxicity. Single-center prospective study of consecutive patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors was conducted during 2015...
Economic analysis of rituximab in combination with cyclophosphamide, vincristin...
Braga, Paula; Carvalho, Susana; Gomes, Marília; Guerra, Lurdes; Lúcio, Paulo; Marques, Herlander; Negreiro, Filipa; Pereira, Catarina; Silva, CatarinaEvaluate costs and benefits of rituximab in combination with cyclophosphamide/vincristine/prednisolone chemotherapy regimen (R-CVP), in previously untreated patients with indolent non-Hodgkin lymphoma (NHL), compared to CVP alone from a Portuguese National Health System (NHS) perspective.Cost-effectiveness (Life Years Gained--LYG) and cost-utility analysis (Quality Adjusted Life Years--QALYs) were performed for...
Recommendations for diagnosis, treatment and monitoring of chronic myeloid leuk...
Almeida, António; Castro, Isabel; Coutinho, Jorge; Guerra, Lurdes; Marques, Herlander; Pereira, Ana MarquesChronic Myeloid Leukemia (CML) is a clonal stem cell disease characterized by the expression of the fusion protein bcr-abl1, which has deregulated tirosine-kinase activity. Tyrosine kinase inhibitors (TKIs), and in particular imatinib, introduced fundamental changes in the treatment of CML, becoming, in most cases, the first-line treatment of choice in the chronic phase of this disease. Compared to other availa...
Leucemia prolinfocítica-T - Uma entidade clínica rara
Costa, Maria João; Carmo, A.; Guerra, Lurdes; Fajardo, J.; Carneiro de Moura, Margarida; Lourenço, Fernanda; Oliveira, J.J.G.; Lacerda, JMFT-Prolymphocytic leukemia is a rare entity and represent 1% of all leukemias. Its clinical and laboratory findings are described. Differential diagnosis and treatment are focused, with greater attenti on on the new purine analogues. Two paradigmatic cases are presented.; A leucemia prolinjocitica T (LPL-T) é uma entida de clínica rara, que representa cerca de 1% das leucemias em geral. Os autores descreve...